AU2019343514B2 - Agent for treatment of dermatological disorders - Google Patents

Agent for treatment of dermatological disorders

Info

Publication number
AU2019343514B2
AU2019343514B2 AU2019343514A AU2019343514A AU2019343514B2 AU 2019343514 B2 AU2019343514 B2 AU 2019343514B2 AU 2019343514 A AU2019343514 A AU 2019343514A AU 2019343514 A AU2019343514 A AU 2019343514A AU 2019343514 B2 AU2019343514 B2 AU 2019343514B2
Authority
AU
Australia
Prior art keywords
polypeptide
seq
ngf
ulcers
chf6467
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019343514A
Other languages
English (en)
Other versions
AU2019343514A1 (en
Inventor
Laura CALZÀ
Bruno Pietro Imbimbo
Gino Villetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of AU2019343514A1 publication Critical patent/AU2019343514A1/en
Application granted granted Critical
Publication of AU2019343514B2 publication Critical patent/AU2019343514B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2019343514A 2018-09-17 2019-09-17 Agent for treatment of dermatological disorders Active AU2019343514B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18194930.6 2018-09-17
EP18194930 2018-09-17
EP18203665.7 2018-10-31
EP18203665 2018-10-31
PCT/EP2019/074767 WO2020058217A1 (en) 2018-09-17 2019-09-17 Agent for treatment of dermatological disorders

Publications (2)

Publication Number Publication Date
AU2019343514A1 AU2019343514A1 (en) 2021-04-15
AU2019343514B2 true AU2019343514B2 (en) 2025-09-25

Family

ID=67989007

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019343514A Active AU2019343514B2 (en) 2018-09-17 2019-09-17 Agent for treatment of dermatological disorders

Country Status (11)

Country Link
US (2) US20220064243A1 (https=)
EP (1) EP3852785A1 (https=)
JP (2) JP2022502359A (https=)
KR (1) KR20210061388A (https=)
CN (1) CN113226350B (https=)
AU (1) AU2019343514B2 (https=)
BR (1) BR112021003820A2 (https=)
CA (1) CA3111158A1 (https=)
MA (1) MA53636A (https=)
MX (1) MX2021002983A (https=)
WO (1) WO2020058217A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023536229A (ja) * 2020-07-27 2023-08-24 ヒューマン セル カンパニー Ｎｇｆバリアント、産生、組成物、及び治療的使用
CA3207296A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating hair loss
US12268677B2 (en) 2022-04-27 2025-04-08 The Penn State Research Foundation 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006893A1 (en) * 2006-07-13 2008-01-17 Lay Line Genomics S.P.A. Muteins of hngf, therapeutic uses and pharmaceutical compositions
US20180086805A1 (en) * 2016-05-20 2018-03-29 Chiesi Farmaceutici S.P.A. proNGF mutants and uses thereof for the preparation of NGF mutants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
EP1482966B1 (en) 2002-03-12 2014-05-14 Bio-Click Technologies Ltd Method and composition for treating skin wounds with epidermal growth factor
WO2010128519A1 (en) 2009-05-04 2010-11-11 Kumar C Jairaj A method for detecting neuropathy and predicting foot ulcer development in human beings with health conditions like diabetes mellitus
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006893A1 (en) * 2006-07-13 2008-01-17 Lay Line Genomics S.P.A. Muteins of hngf, therapeutic uses and pharmaceutical compositions
US20180086805A1 (en) * 2016-05-20 2018-03-29 Chiesi Farmaceutici S.P.A. proNGF mutants and uses thereof for the preparation of NGF mutants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, vol. Vol.10 No.9 (e0136425), JPN6023030947, 2015, pages 1 - 34, ISSN: 0005119402 *

Also Published As

Publication number Publication date
JP2022502359A (ja) 2022-01-11
BR112021003820A2 (pt) 2021-05-25
AU2019343514A1 (en) 2021-04-15
CA3111158A1 (en) 2020-03-26
EP3852785A1 (en) 2021-07-28
JP2025125558A (ja) 2025-08-27
KR20210061388A (ko) 2021-05-27
MA53636A (fr) 2021-12-22
CN113226350B (zh) 2024-09-10
MX2021002983A (es) 2021-05-14
WO2020058217A1 (en) 2020-03-26
US20220064243A1 (en) 2022-03-03
CN113226350A (zh) 2021-08-06
US20250277010A1 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
US20250277010A1 (en) Agent for treatment of dermatological disorders
JP6846063B2 (ja) 異常な皮膚瘢痕化の治療
US20210038690A1 (en) Promoting epithelial regeneration using heparin binding epidermal growth factor like growth factor
KR20080031405A (ko) 상피 재생의 촉진
EP4031117B1 (en) Ngf mutant for use in treatment or prevention of ophthalmic disorders
US12357674B2 (en) Methods for promoting wound healing and hair growth comprising GDNF administration
US12214024B2 (en) Use of APC analogue for wound healing
RU2799211C2 (ru) Средство для лечения дерматологических заболеваний
HK40047629A (zh) 皮肤病治疗剂
HK40047629B (zh) 皮肤病治疗剂
RU2812055C1 (ru) Агент для использования при лечении или профилактике офтальмологических расстройств
WO2022204331A1 (en) Compositions comprising branched kgf-2 derived peptides and methods for use in ocular treatment
AU2004238332A1 (en) Novel fibroblast growth factors and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)